Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

Authors: Russell K. Portenoy, Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, et al
The Journal of Pain, May 2012

Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation, …

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

Authors: Russell K. Portenoy, Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, et al
The Journal of Pain, May 2012

Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation…

Cannabinoid-opioid interaction in chronic pain.

Authors: D. I. Abrams, P. Couey, S. B. Shade, M. E. Kelly, N. L. Benowitz
Clinical Pharmacology & Therapeutics, December 2011

Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty-one individuals with chronic pa…

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.

Authors: Mark A. Ware, Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, et al
CMAJ, 5 October 2010

BACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. METHODS: Adults with post-tra…